Phase II study on first-line treatment of NIV olumab in combination with folfoxiri/bevacizumab in patients with Advanced CO lo R ectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018) | BMC Cancer | Full Text

Phase II study on first-line treatment of NIV olumab in combination with folfoxiri/bevacizumab in patients with Advanced CO lo R ectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018) | BMC Cancer | Full Text

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic col...

Authors:Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno and Carmine Pinto

Citation:BMC Cancer 2020 20:822

Content type:Study protocol

 

Published on: 31 August 2020

• ViewFull Text
 
• ViewPDF